Details for Patent: 11,274,331

Which drugs does patent 11,274,331 protect, and when does it expire?

Patent 11,274,331 protects FIRDAPSE and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 11,274,331

Patent landscape, scope, and claims:

Title:	Methods of administering 3,4-diaminopyridine
Abstract:	Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
Inventor(s):	Garovoy; Marvin R. (Sausalito, CA), Haroldsen; Peter E. (Pacifica, CA), Musson; Donald G. (Larkspur, CA)
Assignee:	SERB SA (Brussels, BE)
Application Number:	17/503,092
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 11,274,331

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Catalyst Pharms	FIRDAPSE	amifampridine phosphate	TABLET;ORAL	208078-001	Nov 28, 2018		RX	Yes	Yes						METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE

International Family Members for US Patent 11,274,331

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2840591
World Intellectual Property Organization (WIPO)	2013003708